Follow
Thomas Fremming Dejgaard
Thomas Fremming Dejgaard
Steno Diabetes Center Copenhagen
Verified email at dadlnet.dk
Title
Cited by
Cited by
Year
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo …
TF Dejgaard, CS Frandsen, TS Hansen, T Almdal, S Urhammer, ...
The lancet Diabetes & endocrinology 4 (3), 221-232, 2016
1312016
Changes in insulin sensitivity precede changes in body composition during 14 days of step reduction combined with overfeeding in healthy young men
SH Knudsen, LS Hansen, M Pedersen, T Dejgaard, J Hansen, GV Hall, ...
Journal of applied physiology 113 (1), 7-15, 2012
1102012
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
CS Frandsen, TF Dejgaard, S Madsbad
The Lancet Diabetes & Endocrinology 4 (9), 766-780, 2016
932016
Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind …
CS Frandsen, TF Dejgaard, JJ Holst, HU Andersen, B Thorsteinsson, ...
Diabetes Care 38 (12), 2250-2257, 2015
822015
Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy
T Hvid, K Winding, A Rinnov, T Dejgaard, C Thomsen, P Iversen, ...
Endocrine-related cancer 20 (5), 621-632, 2013
342013
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
NJ Johansen, TF Dejgaard, A Lund, C Schlüntz, CS Frandsen, JL Forman, ...
The Lancet Diabetes & Endocrinology 8 (4), 313-324, 2020
322020
Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo …
CS Frandsen, TF Dejgaard, HU Andersen, JJ Holst, B Hartmann, ...
Diabetes, Obesity and Metabolism 19 (6), 773-782, 2017
292017
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised …
K Færch, MB Blond, L Bruhn, H Amadid, D Vistisen, KKB Clemmensen, ...
Diabetologia 64, 42-55, 2021
252021
Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: the lira pump trial—a randomized, double …
TF Dejgaard, S Schmidt, CS Frandsen, D Vistisen, S Madsbad, ...
Diabetes, Obesity and Metabolism 22 (4), 492-500, 2020
232020
Emerging drugs for the treatment of obesity
C Martinussen, KN Bojsen-Moller, MS Svane, TF Dejgaard, S Madsbad
Expert opinion on emerging drugs 22 (1), 87-99, 2017
212017
Duration and complications of diabetes mellitus and the associated risk of infective endocarditis
L Østergaard, UM Mogensen, JS Bundgaard, A Dahl, A Wang, ...
International Journal of Cardiology 278, 280-284, 2019
202019
Liraglutide for treating type 1 diabetes
TF Dejgaard, CS Frandsen, JJ Holst, S Madsbad
Expert Opinion on Biological Therapy 16 (4), 579-590, 2016
192016
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
SM Heimbürger, A Brønden, NJ Johansen, TF Dejgaard, T Vilsbøll, ...
Expert Opinion on Pharmacotherapy 20 (5), 501-510, 2019
162019
Non-insulin pharmacological therapies for treating type 1 diabetes
CS Frandsen, TF Dejgaard, S Madsbad, JJ Holst
Expert Opinion on Pharmacotherapy 19 (9), 947-960, 2018
162018
Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a …
TF Dejgaard, FK Knop, L Tarnow, CS Frandsen, TS Hansen, T Almdal, ...
BMJ open 5 (4), e007791, 2015
162015
Continuous glucose monitoring adds information beyond HbA1c in well-controlled diabetes patients with early cardiovascular autonomic neuropathy
J Fleischer, E Laugesen, SL Cichosz, P Hoeyem, TF Dejgaard, ...
Journal of Diabetes and its Complications 31 (9), 1389-1393, 2017
132017
Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes
L Østergaard, CS Frandsen, TF Dejgaard, S Madsbad
Expert Review of Clinical Pharmacology 10 (6), 621-632, 2017
132017
Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes
TF Dejgaard, NB Johansen, CS Frandsen, A Asmar, L Tarnow, FK Knop, ...
Diabetes, Obesity and Metabolism 19 (5), 734-738, 2017
132017
Glycemic control and variability of diabetes secondary to total pancreatectomy assessed by continuous glucose monitoring
CTB Juel, TF Dejgaard, CP Hansen, JH Storkholm, T Vilsbøll, A Lund, ...
The Journal of Clinical Endocrinology & Metabolism 106 (1), 168-173, 2021
72021
59-OR: Liraglutide Preserved Insulin Secretion in Adults with Newly Diagnosed Type 1 Diabetes: The NewLira Trial
TF Dejgaard, CS Frandsen, URD Kielgast, HU Andersen, B Thorsteinsson, ...
Diabetes 68 (Supplement_1), 2019
62019
The system can't perform the operation now. Try again later.
Articles 1–20